Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its CEO Ivor Elrifi and CFO Keeren Shah will present at the Jefferies London Healthcare Conference on November 19.
They will highlight Tiziana’s pipeline and clinical progress, including its lead intranasal anti-CD3 antibody, foralumab, in development for neurodegenerative diseases such as SPMS, Alzheimer’s, MSA, and ALS. Management will also be available for one-on-one investor meetings.